根据名称进行药物检索

Crestor 与 Lofibra Capsules

Crestor 与 Lofibra Capsules互相作用以及同时服用的可能性。

检测结果:

Crestor <> Lofibra Capsules

现实性: 25.07.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

用诺贝特一起伐他汀可以增加风险的副作用，例如肝脏损坏和一个罕见的，但严重的情况称为横纹肌瘤，涉及到崩溃的骨骼肌肉组织。在某些情况下，横纹肌瘤可造成肾脏损伤甚至死亡。你可能需要的剂量调整或更频繁的监测通过你的医生到安全地使用这两种药物。谈谈你的医生如果你有任何疑问或关切的问题。你的医生可能已经知道的风险，但是已确定这是最好的治疗并采取适当的预防措施和监控你的密切对任何潜在并发症。让你的医生立即知道如果你有无法解释的肌肉疼痛、温柔、或弱点而采取这些药物，特别是如果这些症状是伴随着发烧或暗色的尿液。你也应该立即寻求医疗照顾，如果你开发的热、冷、关节疼痛或肿胀、不寻常或出血瘀伤、皮疹、瘙痒，食欲不振、疲劳、恶心、呕吐、暗色的尿液和/或黄皮肤或眼睛，因为这些可能的迹象和症状的肝脏损伤。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免严重的肌病和横纹肌瘤已报告期间同时使用英国政府CoA还原酶抑制剂和纤维酸衍生物，尤其是吉非贝齐。吉非贝齐已有报道显着增加的等离子体浓度的一些英国政府CoA还原酶抑制剂和/或它们的活性代谢物，包括洛伐他的辛伐他汀、普,立伐他汀，并伐他汀(但不氟伐). 高级别的英国政府CoA还原酶抑制活动等离子增加相关风险的骨骼肌肉毒性。肌病表现为肌肉疼痛和/或弱点相关的严重升高的肌酸激酶超过十倍正常上限已经报道的偶尔。横纹肌瘤也已发生很少，这可能是伴随着急性肾功能衰竭次要myoglobinuria，并可能导致死亡。其他的贝特没有显示出明显影响的药物动力学的英国政府CoA还原酶抑制剂。然而，使用单独贝特也已经与发展相关的肌病，从而有效的互动可能发生。

管理：并行使用的纤维酸衍生物和英国政府CoA还原酶抑制剂通常应该避免，除非受益于进一步改建脂水平预计将超过潜在的风险。另外的贝特为英国政府CoA还原酶抑制剂治疗通常提供小额降低LDL胆固醇，但进一步削减的甘油三酯和增加在高密度脂蛋白胆固醇可以获得。如果结合的规定，贝特等其他比吉非贝齐可能是可取的，随着较低的初步剂量的HMG CoA还原酶抑制剂。如果吉非贝齐的使用，伐他汀每日的剂量不应超过10毫克。洛瓦斯汀标签的建议，剂量不超过20毫克的日当规定与吉非贝齐或其他贝特类。所有患者的治疗与英国政府CoA还原酶抑制剂和/或贝特应立即报告任何无法解释的肌肉疼痛、温柔弱，尤其是如果伴随高烧、不适和/或暗色的尿液。治疗应该停止，如果肌酸磷酸激酶是明显升高，在没有剧烈的运动或者如果肌病是无怀疑或诊断。此外，患者应密切监测肝毒性。

来源

Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ "Gemfibrozil greatly increases plasma concentrations of cerivastatin." Clin Pharmacol Ther 72 (2002): 685-91
Mastroianni CM, dEttorre G, Forcina G, Lichtner M, Corpolongo A, Coletta S, Vullo V "Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia." AIDS 15 (2001): 820-1
"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc, Mississauga, ON.
Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998): 368-9
Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD "Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil." Am J Health Syst Pharm 57 (2000): 461-4
"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb, Princeton, NJ.
Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76
Tomlinson B, Lan IW "Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: Is the interaction predictable?." Am J Med 110 (2001): 669
Schwandt P "Drug interactions and side effects of hypolipidemic drugs." Int J Clin Pharmacol Biopharm 17 (1979): 351-6
Jacob SS, Jacob S, Williams C, Deeg MA "Simvastatin, fenofibrate, and rhabdomyolysis." Diabetes Care 28 (2005): 1258
Abdul-Ghaffar NU, el-Sonbaty MR "Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy." J Clin Gastroenterol 21 (1995): 340-1
"Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.
Williams D, Feely J "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors." Clin Pharmacokinet 41 (2002): 343-70
Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999): 1146
Fujino H, Shimada S, Yamada I, Hirano M, Tsunenari Y, Kojima J "Studies on the interaction between fibrates and statins using human hepatic microsomes." Arzneimittelforschung 53 (2003): 701-7
Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990): 71-5
Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74
Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ "Gemfibrozil inhibits CYP2C8-mediatd cerivastatin metabolism in human liver microsomes." Drug Metab Dispos 30 (2002): 1352-6
"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Davidson MH "Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions." Exp Opin Drug Saf 5 (2006): 145-56
Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE "Pharmacokinetics of the combination of fluvastatin and gemfibrozil." Am J Cardiol 76 (1995): a80-3
Bruno-Joyce J, Dugas JM, MacCausland OE "Cerivastatin and gemfibrozil-associated rhabdomyolysis." Ann Pharmacother 35 (2001): 1016-9
Alexandridis G, Pappas GA, Elisaf MS "Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil." Am J Med 109 (2000): 261-2
Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ "Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate." Clin Pharmacol Ther 69 (2001): 340-5
Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998): 155-62
Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ "Plasma concentrations of active simvastatin acid are increased by gemfibrozil." Clin Pharmacol Ther 68 (2000): 122-9
Tal A, Rajeshawari M, Isley W "Rhabdomyolysis associated with simvastatin-gemfibrozil therapy." South Med J 90 (1997): 546-7
Prueksaritanont T, Zhao JJ, Ma B, et al. "Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins." J Pharmacol Exp Ther 301 (2002): 1042-51
Rodriguez ML "Cerivastatin-induced rhabdomyolysis." Ann Intern Med 132 (2000): 598
Unal A, Torun E, Sipahioglu MH, et al. "Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients." Intern Med 47 (2008): 1017-9
"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical, Abbott Park, IL.
Roca B, Calvo B, Monferrer R "Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy." Ann Pharmacother 36 (2002): 730-1
"Product Information. Baycol (cerivastatin)." Bayer, West Haven, CT.
"Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.
Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez-Lirola A, Rodriguez-Rodriguez E, Santolaria-Fernandez F "Acute rhabdomyolysis associated with cerivastatin therapy." Arch Intern Med 161 (2001): 893
"Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.
Ireland JH, Eggert CH, Arendt CJ, Williams AW "Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate." Ann Intern Med 142 (2005): 949-50
Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH "Effects of fibrates on metabolism of statins in human hepatocytes." Drug Metab Dispos 30 (2002): 1280-7
Schneck DW, Birmingham BK, Zalikowski JA, et al. "The effect of gemfibrozil on the pharmacokinetics of rosuvastatin." Clin Pharmacol Ther 75 (2004): 455-63
Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, Joyce DM, Gantner SE "Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders." Am Heart J 138 (1999): 151-5
Staffa JA, Chang J, Green L "Cerivastatin and reports of fatal rhabdomyolysis." N Engl J Med 346 (2002): 539-40
Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ "Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance." Clin Pharmacol Ther 73 (2003): 538-44